Evista For Sale - Buy Raloxifene Online
Evista (Raloxifene) is one of the most effective SERMs used to treat osteoporosis in women. This drug is similar to Tamoxifen: they both act as anti-estrogens in target tissues. The main difference between them is that Raloxifene is active not only in the breast tissue, but in the uterine and bone tissue as well. It helps prevent bone fragility and keep the normal level of endogenous estradiol. Raloxifene copes better with gynecomastia than Tamoxifen. According to experts, it works 2 times more effective than Tamoxifen. Besides, Raloxifene has a stronger effect in the breast tissue.
Raloxifene also affects the production of cholesterol, but to a lesser extent than other drugs. Frankly speaking, this is a welcome alternative to Tamoxifen.
Raloxifene is a new SERM that is important for women for its antiestrogenic function in the uterus (as compared to Tamoxifen or Clomiphene). In this respect, the last two drugs can cause cervical cancer, whereas Raloxifene actually helps fight this problem. Therefore it is of great value for women.
Raloxifene was originally developed for cancer therapy. It was later approved by the FDA as a treatment for osteoporosis in women during menopause. It is also effective in the prevention of cardiovascular disease, breast cancer, gynecomastia, prostate cancer, acromegaly, and uterine cancer. As an anti-estrogen agent, it is widely used in bodybuilders for the suppression of estrogenic side effects.
Raloxifene was produced by Eli Lilly & Company in the United States and approved in 1997. At first, this non-steroidal benzothiophene derivative was used for the treatment of osteoporosis (as it increases bone density). In 2007, it began to be used to treat breast cancer. This is a very popular drug, which is used for today in more than 50 countries.
Evista (Raloxifene) for human use
Raloxifene is classified as a selective estrogen receptor modulator with agonistic and antagonistic properties. Evista acts as an agonist on body tissues not related to reproduction and as an antagonist on reproductive tissues. This drug reduces the process of bone resorption and normalizes the calcium balance in the body, primarily by reducing calcium loss in the urine. It does not cause endometrial proliferation, postmenopausal bleeding or endometrial cancer. Besides, it does not cause hyperplasia of mammary tissue. Raloxifene reduces swelling and breast tenderness, reduces levels of total cholesterol and LDL. The drug significantly reduces the risk of osteoporotic vertebral fractures in patients with previous fractures.
Evista is used for the prevention of osteoporosis in postmenopausal women and patients after hysterectomy. This is the only drug approved for treatment and prevention of osteoporosis in women. Studies have shown that this drug can stop bone thinning and help build strong bones. Raloxifene can help prevent bone loss and reduce the risk of vertebral fractures. Raloxifene can also prevent the occurrence of invasive breast cancer after menopause. It acts as an estrogen in some parts of the body (such as bones). As for the other parts of the body (uterus and breast), this drug acts as a blocker of estrogen. It does not eliminate various climacteric symptoms.
Evista (Raloxifene) doses
Evista is available in the form of tablets of 60 mg. The recommended dose is 60 mg per day. Take one tablet regardless of the meal in combination with calcium and vitamin D. If you missed the reception of the drug, take it as soon as remember. However, an additional dose is not necessary. Do not take a double dose at once.
Elderly patients should not change the dosing regimen. The recommended dose for athletes is 30-60 mg per day (to avoid the side effects of AAS).
Evista (Raloxifene) side effects
Common side effects include hot flushes, headache, weakness, leg cramps, swelling, sweating, depression, weight gain, nausea, vomiting and diarrhea. Less common side effects: chest pain, vaginal bleeding, thrombosis, impaired vision. In rare cases, the therapy can lead to stroke, transient ischemic attack, pulmonary embolism, deep vein thrombosis, gastric ulcer.
Raloxifene increases the risk of blood clots in the veins. It also increases the risk of stroke (but not other types of cardiovascular disease). The therapy may also cause deep vein thrombosis and pulmonary embolism. These side effects are very serious. Women should not take this drug if they have blood clots or have certain risk factors for stroke and heart disease.
Contraindications: thromboembolism, deep vein thrombosis, pulmonary embolism and retinal vein occlusion, pregnancy, hypersensitivity to Raloxifene.
Drugs with antiestrogenic properties can harm the fetus. Therefore, Evista should not be used during pregnancy.
Evista (Raloxifene) special instructions
It is not recommended to use Evista in combination with estrogens. If you have any diseases or conditions that lead to prolonged immobilization, the therapy should be cancelled until full mobility is restored. Anticoagulants may cause a slight decrease in prothrombin time. Cholestyramine significantly reduces the absorption and enterohepatic circulation of Raloxifene.
It is not recommended to use Evista in patients with severe hepatic impairment. Patients should use additional calcium supplements during treatment.
It is not known whether Raloxifene is excreted in breast milk. However, experimental studies have shown that Raloxifene therapy during breastfeeding is not recommended.
Evista (Raloxifene) in bodybuilding
In fact, Evista is an anti-estrogen drug that has properties of both antagonist and agonist of estrogen. This means it acts as an estrogen (in bone tissue) and an anti-estrogen (in the uterus and mammary tissue), depending on the place of absorption.
Evista basically acts as an anti-estrogen in the male body. Its effect is similar to the effect of the most popular and commonly used anti-estrogens such as Tamoxifen (Nolvadex) and Clomiphene citrate (Clomid). These are two drugs that are effective in blocking the process of absorption of estrogen. Many bodybuilders and athletes take these drugs during steroid cycles to prevent the above-mentioned absorption of estrogen. Lack of absorption of estrogen significantly reduces the side effects but also prevents the development of gynecomastia. Evista is considered the most effective in the treatment of gynecomastia (gynecomastia is reduced completely in most cases).
Advantages: Evista is the best drug against gynecomastia. It has less potential for hepatotoxicity than Tamoxifen.
Disadvantages: Evista may cause serious side effects (abnormal blood clotting, severe shortness of breath, blurred vision). Evista can also cause irritability, mood swings, stiffness or pain in the joints, libido problems.
Evista is usually taken after the end of a steroid cycle, which may include Winstrol, Anavar, Primobolan, Testosterone (Propionate, Enanthate and Cypionate), Trenbolone, Turinabol, Deca and Halotestin.